Transforming lymphoma care: conversations with experts
Transforming lymphoma care: conversations with experts
Cell and gene therapies are rapidly changing the landscape for relapsed and refractory lymphoma, offering new hope through targeted approaches and personalized strategies. In this collection of recorded talks, experts explore advances in the field, discuss clinical outcomes, and future directions for care options.
Outcomes of low-cost, point-of-care manufactured CAR T cell therapy for B cell acute leukemia and non-hogkin lymphoblastic lymphoma in Vietnam
Purpose: This study aims to analyze the safety and primary efficacy of point-of-care CD19 CAR T cell therapy produced locally at low cost for the treatment of CD19+ B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in Vietnam.
Methods: A phase 1 clinical trial was conducted from August 2023 to March 2025. CD19 CAR T cells for 8 ALL patients and 8 NHL patients were manufactured using the automated CliniMACS Prodigy® System. CAR T cells were infused with doses ranging from 0.54 to 2.17×106 cells/kg.
Results: The number and percentage of CAR T cells at harvest were comparable between the 12-day and 8-day culture groups; however, viability was significantly better in the latter group (p=0.01). Upon treatment, the most common side effects included cytokine release syndrome (13 patients) and neurological toxicity (2 patients). No mortality related to CAR T therapy was observed. All ALL patients achieved complete remission after CAR T cell infusion on day 30. At 6 months, 5 patients (62.5%) remained in complete remission. 7 out of 8 NHL patients achieved complete remission on day 90, and 6 remained in complete remission at 6 months. One patient is awaiting assessment.
The total cost of CAR T cell therapy was approximately $140,000 per patient, with around $80,000 allocated to the CAR T product and $60,000 for treatment costs.
Conclusion: CD19 CAR T products can be produced at low cost. CAR T treatment is relatively safe and offers a promising therapeutic option for refractory/relapsed CD19+ NHL and ALL in a developing country like Vietnam.
Low-cost CD19 CAR T can be produced for refractory/relapsed CD19+ NHL and ALL.
Nguyen Thanh Liem, MD @ MACS Cell and Gene Therapy Days 2025
Prof. Nguyen Thanh Liem, MD
Director of the Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
rof. Nguyen Thanh Liem is a pioneer and innovator in pediatric endoscopic surgery and stem cell transplantation. He graduated from Hanoi Medical University in 1976 and completed medical residency program in Surgery at Viet Duc Hospital in 1979. He defended his PhD thesis in 1991 and was appointed as a Medical Professor in Surgery in 2009.
He is an internationally recognized inventor for his seven advanced operative techniques in pediatric surgery. Regarding stem cell studies, Prof. Liem is a pioneer of using stem cell therapy for unmet diseases in children such as cerebral palsy due to oxygen deprivation, due to neonatal icterus, due to intracranial hemorrhage, neurological sequelae after near death drowning, autism, bronchopulmonary dysplasia, and liver cirrhosis due to biliary atresia. Throughout his career, he has been in charge of a number of important positions such as Director of Vietnam National Children Hospital from 2002 to 2012; Director of Vinmec International Hospital from 2013-2016; Vice President of Asian Association of Pediatric Surgery; President of Vietnam Association of Pediatric Surgery. Currently, Prof. Liem is the director of Vinmec Research Institute of Stem Cell and Gene Technology.
He has published 135 studies on the international journals and over 200 papers on domestic journals. He is the editor and author of six chapters of the book titled, “Cell Therapy: Stem Cells and Regenerative Medicine”, which is shortly published by Springer Nature in 2025. He is also the co-author of surgery pediatrics textbooks published in the UK and the US, such as Operative Pediatric Surgery, Ashcraft’s Pediatric Surgery, and Pediatric Laparoscopic and Thoracoscopic Surgery.
Prof. Nguyen Thanh Liem has been invited to give lectures and performed demonstrative surgeries in many countries including the US, France, Netherlands, Italia, Australia, Japan, India, South Korea, and more.
By his dedicated and delightful contributions to the medical practices and research, he has been honored many prestige awards conferred by the Vietnam government like the Ho Chi Minh Award, National Labor Hero Medal and Award of Vietnam Talent.
In 2018, he has been awarded the 2018 Nikkei Asia Prize in the Science and Technology category thanks to his contribution to develop and popularize pediatric endoscopic surgery in Asia and the world. He is categorized in the top 100 scientists in Asia by the Singapore Journal in 2019.
Developing off-the-shelf CAR NK cells targeting CD70: Updates from preclinical studies to early clinical trials in an academic setting
The ability to re-direct the intrinsic power of the immune system toward cancer has translated into unprecedented outcomes in the treatment of patients with otherwise incurable diseases. CAR NK cells have emerged as a promising immunotherapy for cancer due to NK cells' innate ability to kill tumors and their safety in the allogeneic setting.
CD70, the natural ligand for CD27, is an attractive "pan-cancer antigen", due to its high expression in multiple hematologic and solid cancers. Thus, we sought to develop chimeric antigen receptor (CAR)-engineered NK cells to target CD70. We took advantage of the physiologic CD70/CD27 interaction to design a CAR construct that contained the human CD27 (the natural receptor of CD70) as an extracellular domain.
We generated various second-generation CAR constructs that differ in costimulatory domains (NKG2D, DAP10, DAP12, CD28, and 41-BB). The CD3ζ chain was used as a signaling domain, and all the CAR constructs also included IL-15 to enhance in vivo proliferation and persistence. Cord blood (CB)-derived NK cells were efficiently transduced with a retroviral vector expressing various CAR constructs and were subjected to an in vitro functional screen against various cancer cells to evaluate the best construct. Those CAR constructs were further evaluated on an in vivo screen of the hematologic and solid cancer model, and we determined that incorporation of CD28, a costimulatory molecule not naturally expressed by mature NK cells, resulted in superior CAR-NK cell efficacy, and tumor control in multiple xenograft models of hematologic and solid tumors.
Based on these preclinical findings, a Phase I/II clinical study is now being conducted for CD70-expressing hematologic malignancies (NCT05092451) as well as solid cancers (NCT05703854) to assess the safety and effectiveness of CD70 CAR NK cells.
Sunil Acharya, PhD @ Miltenyi Biotec Cell and Gene Therapy Days 2024
Sunil Acharya, PhD
Principal Research Scientist, MD Anderson Cancer Center, USA
Sunil Acharya, PhD, is a graduate of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, where he earned his doctoral degree in cancer biology. Currently serving as a Principal Research Scientist in the laboratory of Dr. Katy Rezvani at MD Anderson Cancer Center, his primary research focus lies in advancing cellular therapy, particularly exploring the potential of natural killer (NK) cells as therapeutic tools. He leads the CD70 CAR NK project, which is in Phase I/II clinical trial for both hematologic and solid cancers.
Transposon-based system for CAR T cell therapy
Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. However, the widening use of cell therapy is hampered by the accessibility to viral vectors that are commonly used for T cell transfection.
We report our experience of a non-viral Sleeping Beauty transposon system for the genetic modification of cytokine-induced killer (CIK) cells to express CARs, paving the way for innovative treatments for hematologic malignancies. Clinical results from a phase I-II trial (NCT03389035) are described, highlighting the safety and efficacy of CARCIK-CD19 therapy in patients with relapsed B cell acute lymphoblastic leukemia (B-ALL) following hematopoietic stem cell transplantation (HSCT).
Furthermore, a comprehensive overview of our advancements in the non-viral CAR-CIK platform is given. This includes streamlining the production process and harnessing cord blood (CB) as a source for CAR-CIK cell production, paving the way for a more readily available "off-the-shelf" CAR T cell therapy. Finally, the presentation underscores the remarkable versatility of the non-viral platform through the preclinical characterization of next-generation CAR-CIK cells tailored to acute myeloid leukemia (AML). This entails introducing a dual CAR strategy aimed at optimizing both efficacy and safety, targeting CD123 and CD33 antigens and “armored” CAR-CIK cells carrying CD33CAR and CXCR4, engineered to enhance their homing capabilities within the bone marrow niche.
Prof. Andrea Biondi, MD @ Miltenyi Biotec Cell and Gene Therapy Days 2023
Prof. Andrea Biondi, MD
Director of Pediatric Department and Tettamanti Research Center, University of Milano-Bicocca Monza, Italy
Prof. Andrea Biondi, MD, is Full Professor of Pediatrics at the Department of Medicine and Surgery, and Director of the Pediatric Clinic and School of Specialization in Pediatrics at the University of Milan-Bicocca.
He is acting as Scientific Director of the IRCCS San Gerardo dei Tintori Foundation in Monza. He is also Scientific Director of the M. Tettamanti Research Center and of the Stefano Verri Cell and Gene Therapy Laboratory.
He was a research associate of the Dana Farber Cancer Institute at Harvard Medical School in Boston and the Ontario Cancer Institute in Toronto. From 2004 to 2008, he was President of SIOP Europe, and from 2012 to 2015, President of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Between 2016 and 2022, he was President of the International BFM Study Group (I-BFM-SG).
He is a member of several scientific associations and is actively involved in the review and fundraising programs of international organizations and agencies. At the moment, his research activity focuses on the molecular genetics of leukemia in childhood and on immunotherapy and therapy via CAR T applied to leukemia.
Point-of-care CAR T cell manufacturing in Canada: CLIC-01 CD19 clinical trial
Developing a country-wide program to make lifesaving CAR T cell therapy accessible to patients is no small feat. In Canada, Dr. Natasha Kekre has been instrumental in driving the Canadian-Led Immunotherapies in Cancer (CLIC) research program to make this a reality. In this webinar, Dr. Kekre of The Ottawa Hospital will present the multitude of unique challenges involved and how the program overcame them to offer CAR T cell therapy to patients across Canada who may otherwise be out of options.
Webinar given by Dr. Natasha Kekre, BSc, MD, MPH, FRCPC
Dr. Natasha Kekre, BSc, MD, MPH, FRCPC
Transplant and Cellular Therapy Program, The Ottawa Hospital, Canada
Natasha Kekre, BSc, MD, MPH, FRCPC, is a hematologist in the Transplant and Cellular Therapy Program at The Ottawa Hospital. She is also an associate scientist at the Ottawa Hospital Research Institute and Associate Professor of Medicine at the University of Ottawa.
She completed her Bachelor of Science at the University of Windsor and then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in internal medicine and hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston, MA with a Master’s in Public Health from Harvard University. Her research is focused on developing early-phase clinical trials and moving homegrown therapeutic strategies to patients to treat hematologic malignancies.
You have previously chosen International as your location.
What do you want to do?